Literature DB >> 1730214

[A lethal course in pseudomembranous enterocolitis during the parenteral administration of vancomycin and imipenem].

M Arning1, A Gehrt, M Wolf, C Aul, H Chlebowski, U Hadding, W Schneider.   

Abstract

A 48-year-old woman required mechanical ventilation after aortic valve replacement for decompensated aortic valve stenosis when bleeding complications developed and rethoracotomy had to be performed. Acute renal failure necessitated haemodialysis. Septic fever of unknown aetiology failed to respond to oxacillin, cefotaxim and tobramycin. The endotracheal cannula and central venous catheter were changed on the 24th postoperative day and the antibiotic treatment altered to 250 mg imipenem and 125 mg vancomycin three times daily intravenously. The fever soon subsided, but recurred on the 32nd postoperative day, accompanied by increasing leucocytosis. The patient was obstipated but had no intraabdominal signs. Four days later ultrasonography demonstrated thickening of the intestinal wall and coloscopy showed typical pseudomembranous colitis. Intestinal contents were positive for Clostridium difficile toxin. Despite immediate rectal and intragastric administration of 250 mg vancomycin four times daily the patient died of pseudomembranous colitis, confirmed at autopsy. The case demonstrates that vancomycin cannot always prevent the development of pseudomembranous colitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730214     DOI: 10.1055/s-2008-1062285

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

Review 1.  Clostridium difficile causing acute renal failure: case presentation and review.

Authors:  Jasmin Arrich; Gottfried-H Sodeck; Gurkan Sengolge; Christoforos Konnaris; Marcus Mullner; Anton-N Laggner; Hans Domanovits
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

Review 2.  Adverse effects of monobactams and carbapenems.

Authors:  G Alván; C E Nord
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.